Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings GlaxoSmithKline Pharmaceuticals Limited: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Highlights: GlaxoSmithKline Pharmaceuticals Limited
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses: GlaxoSmithKline Pharmaceuticals Limited
  • With a 2027 P/E ratio at 31.24 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is not the most generous with respect to shareholders' compensation.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Rating Financials

GlaxoSmithKline Pharmaceuticals Limited SectorIndia

Fundamentals

-

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

-

ROA

-

ROCE

-

ROE

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

GlaxoSmithKline Pharmaceuticals Limited SectorIndia

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

-

CAPEX/Revenue

More ratings

Rating Consensus

GlaxoSmithKline Pharmaceuticals Limited SectorIndia

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

GlaxoSmithKline Pharmaceuticals Limited SectorIndia

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

GlaxoSmithKline Pharmaceuticals Limited SectorIndia

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
3.72B - - - -
1,035B
A
574B
BBB
397B -
AA
- -
324B
AA
281B
A
278B
AAA
193B
A
191B
A
156B
AA
Average 343.37B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. 500660 Stock
  4. Ratings GlaxoSmithKline Pharmaceuticals Limited
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!